STING1 and neoplasm: Recent studies have increasingly focused on the co‐delivery of STING agonists and peptide antigens using nanotechnology, exploring the synergistic potential of nanoadjuvants to enhance STING pathway activation and tumor vaccine efficacy.[93, 100] These approaches leverage advanced nanoplatforms to address immunogenicity and delivery efficiency challenges, offering new avenues for cancer immunotherapy.